What AI says about Verge Genomics

Verge Genomics is building an enduring biotechnology company that uses an all-in-human, AI-powered drug-discovery platform to unlock new therapies at scale, leveraging a proprietary multi-omics database from human tissue. The company translates these insights into drug candidates on its internal biology and chemistry platforms, starting in humans, with VRG50635 (a PIKfyve inhibitor) in clinical trials for ALS and a pipeline focused on Parkinson's Disease, Frontotemporal Dementia, and other devastating diseases. Verge collaborates with industry partners and emphasizes a team-oriented culture, based in San Francisco.